Avalon Biomedical (Management) Limited (“ABM” or together with its subsidiaries, the “Group”) is pleased to announce that the Avalon Photonics’ KangaLite Phototherapy System has received registration approval for Class II medical device by National Provincial Medical Products Administration (NMPA) under the Pilot Program for the Market Authorization Holder (MAH) system. It only took 13 months from filing acceptance to the final approval.

KangaLite is designed to make the treatment of neonatal jaundice at home possible. It is a wearable phototherapy device which promotes kangaroo care as well as breast-feeding. More importantly, KangaLite offers an ideal option for home phototherapy during COVID-19 pandemic.